What is Syncardia Systems?
Headquartered in Tucson, Arizona, Syncardia Systems is the developer and manufacturer of the world's first and only FDA, Health Canada, and CE-approved Total Artificial Heart. The company serves a vital niche in the medical device sector, providing a temporary, life-sustaining solution for patients with end-stage heart failure affecting both sides of the heart. Beyond the artificial heart itself, Syncardia produces the Freedom portable driver, a critical innovation that allows clinically stable patients to transition from hospital-based care to home environments, significantly improving quality of life while awaiting a transplant.
How much funding has Syncardia Systems raised?
Syncardia Systems has raised a total of $42.3M across 7 funding rounds:
Series B
$3.7M
Series D
$10.3M
Private Equity
$5M
Debt
$14M
Private Equity
$6.4M
Debt
$1M
Debt
$1.9M
Series B (2004): $3.7M, investors not publicly disclosed
Series D (2009): $10.3M led by Highway 12 Ventures
Private Equity (2011): $5M, investors not publicly disclosed
Debt (2013): $14M featuring Athyrium Capital Management and SWK Holdings
Private Equity (2014): $6.4M, investors not publicly disclosed
Debt (2020): $1M with participation from PPP
Debt (2021): $1.9M led by PPP
Key Investors in Syncardia Systems
Athyrium Capital Management
Athyrium Capital Management is a leading investment management platform focused on structured investments in the global healthcare sector, providing financing solutions for pharmaceutical and biotechnology firms.
SWK Holdings
SWK Holdings is a life science specialty finance company that provides innovative capital solutions to institutions and inventors within the global healthcare industry.
Highway 12 Ventures
Highway 12 Ventures is a venture capital and private equity firm based in Boise, Idaho, that focuses on supporting growth-stage companies through strategic financial backing.
What's next for Syncardia Systems?
With the recent infusion of capital, Syncardia Systems is well-positioned to scale its manufacturing capabilities and expand the reach of its portable driver technology. The strategic focus will likely remain on optimizing the clinical outcomes for patients with biventricular failure and strengthening the supply chain for its life-critical devices. As the company navigates the complexities of the global healthcare market, this financing provides the necessary liquidity to support ongoing research and development, ensuring that Syncardia remains at the forefront of mechanical circulatory support and cardiac innovation.
See full Syncardia Systems company page
